FDA Brief

Warning letters Drugs

FDA warning letter to

Avaria Health & Beauty Corp.

High riskIssued Aug 3, 2023Posted Aug 8, 2023Center for Drug Evaluation and Research | CDER

FDA cites Avaria Health & Beauty for manufacturing-rule violations in OTC drugs, including missing glycerin identity testing and weak quality unit.

What happened

FDA reviewed records Avaria submitted after FDA's January 25, 2023 request for records under federal law; this was a records review, not an inspection. FDA found the company did not test each shipment and lot of high-risk components such as glycerin for identity, including a standard test for diethylene glycol (DEG) and ethylene glycol (EG), and that its quality unit did not adequately approve or reject components. FDA placed the firm on Import Alert 66-40, which can stop U.S. imports, on April 14, 2023.

What FDA found

  1. Avaria did not test each shipment and lot of high-risk incoming components, including glycerin, for identity with the test that detects DEG and EG.

    21 CFR 211.84(d)(1)
  2. Avaria's quality unit did not effectively use its authority to approve or reject components in its materials system.

    21 CFR 211.22(a)

What FDA wants

FDA tells Avaria to respond in writing within 30 working days with corrective actions, including DEG and EG test results within 30 calendar days, a risk assessment for in-date products, component testing plans, and quality-unit remediation. If corrective actions cannot be completed in 15 working days, the company must explain the delay and give a completion schedule.

Who should pay attention

  • brands that buy OTC drugs or hand sanitizer from this contract manufacturer
  • companies using glycerin or other high-risk components in drug products
  • U.S. importers and distributors of Avaria products

This is a summary. Read the original letter on fda.gov.

Avaria Health & Beauty Corp.'s FDA history

  1. Avaria Health & Beauty Corp.

    FDA warns Canadian maker Avaria Health & Beauty over CGMP failures in OTC drug products, including skipped ingredient identity testing.

    High risk

Full company page

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk